<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27737407</article-id><article-id pub-id-type="pmc">5062706</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Anticoagulation Quality and Complications of using Vitamin K
Antagonists in the Cardiac Surgery Outpatient Clinic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>da Costa</surname><given-names>M&#x000e1;rio Augusto Cray</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Krum</surname><given-names>Lucas Kraeski</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Geraldino</surname><given-names>Juliana da Silva</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Schafranski</surname><given-names>Marcelo Derbli</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Gomes</surname><given-names>Ricardo Zanetti</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Reis</surname><given-names>Elise Souza dos Santos</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, PhD</role></contrib></contrib-group><aff id="aff1"><label>1</label>Universidade Estadual de Ponta Grossa (UEPG), Ponta
Grossa, PR, Brazil and Santa Casa de Miseric&#x000f3;rdia de Ponta Grossa, Ponta
Grossa, PR, Brazil</aff><aff id="aff2"><label>2</label>Universidade Estadual de Ponta Grossa (UEPG), Ponta
Grossa, PR, Brazil</aff><author-notes><corresp id="c1"><bold>Correspondence Address:</bold> M&#x000e1;rio Augusto Cray da
Costa, Universidade Estadual de Ponta Grossa - Departamento de Medicina, Av.
General Carlos Cavalcanti, 4748 - Bloco M - Uvaranas, Ponta Grossa, PR, Brazil
Zip code: 84030-900. E-mail: <email>drmarioaugusto@uol.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>May-Jun</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>May-Jun</season><year>2016</year></pub-date><volume>31</volume><issue>3</issue><fpage>239</fpage><lpage>245</lpage><history><date date-type="received"><day>10</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>INTRODUCTION:</title><p>In patients with mechanical prosthetic heart valves or atrial fibrillation
requiring anticoagulation to prevent thromboembolic events, several factors
influence adherence and anticoagulation complications.</p></sec><sec><title>OBJECTIVE:</title><p>To evaluate the factors that interfere with the quality and complications of
anticoagulation with vitamin K antagonists.</p></sec><sec><title>METHODS:</title><p>A retrospective cohort study of 100 patients, in the period from 2011 to
2014, was performed. Anticoagulation conditions in the last year, regarding
the presence of complications (embolisms/bleeding) and inadequate treatment
were assessed: achievement of less than 8 annual prothrombin times and
International Normalized Ratio outside therapeutic target in more than 40%
of prothrombin times.</p></sec><sec><title>RESULTS:</title><p>There were 31 complications (22 minor bleeding without hospitalization and 9
major complications: 7 bleeding with hospitalization and two emboli); 70
were with International Normalized Ratio outside the target in more than 40%
of the tests and 36 with insufficient number of prothrombin times.
Socioeconomic factors, anticoagulant type and anticoagulation reason had no
relationship with complications or with inadequate treatment. There were
more complications in patients with longer duration of anticoagulation
(<italic>P</italic>=0.001). Women had more International Normalized
Ratio outside the target range (OR 2.61, CI:1.0-6.5;
<italic>P</italic>=0.04). Patients with lower number of annual prothrombin
times had longer times of anticoagulation (<italic>P</italic>=0.03), less
annual consultations (<italic>P</italic>=0.02) and less dose adjustments
(<italic>P</italic>=0.003). Patients with longer duration of
anticoagulation have more complications (<italic>P</italic>=0.001).</p></sec><sec><title>CONCLUSION:</title><p>There was a high rate of major complications and International Normalized
Ratio was outside the goal. Less annual prothrombin times was related to
longer duration of anticoagulation, less annual consultations and less dose
adjustments. More major complications occurred in patients with longer
duration of anticoagulation.</p></sec></abstract><kwd-group><kwd>Anticoagulants</kwd><kwd>Prostheses and Implants</kwd><kwd>Atrial Fibrillation</kwd></kwd-group></article-meta></front><body><p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="15%" span="1"/><col width="85%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Abbreviations, acronyms &#x00026;
symbols</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AF</td><td rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td rowspan="1" colspan="1">INR</td><td rowspan="1" colspan="1">= International Normalized Ratio</td></tr><tr><td rowspan="1" colspan="1">OR</td><td rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td rowspan="1" colspan="1">PT</td><td rowspan="1" colspan="1">= Prothrombin time</td></tr><tr><td rowspan="1" colspan="1">SUS</td><td rowspan="1" colspan="1">= Unified Health System</td></tr></tbody></table></table-wrap>
</p><sec sec-type="intro"><title>INTRODUCTION</title><p>When the surgeons need to replace a heart valve with a prosthesis, they should take
into account the life expectancy of the patient and the risk of embolism to decide
on the use of biological or mechanical prosthesis<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Still, in
a patient with atrial fibrillation (AF) it is necessary to weigh the risks and
benefits of anticoagulation<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Important analysis tools such as
CHADS and CHA<sub>2</sub>DS<sub>2</sub>VASc scores determine the risk of embolic
event setting points according to the comorbidities associated with the AF, on the
other hand, the HAS-BLED index establishes the risk of bleeding in these
patients<sup>[<xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Such tools help in decision making, but do not
take into account socioeconomic and cultural factors that gain expression especially
in populations predominantly composed of Brazil's public health system users, called
Unified Health System (SUS).</p><p>There is not a calculation tool either that safely guides surgeons about the risk of
thromboembolic and bleeding complications in patients with mechanical prostheses
against the risks of multiple reoperations in patients with bioprosthetic valves.
Studies have not demonstrated superiority of one type of prosthesis in relation to
each other in terms of mortality, and the sensitivity and experience of each surgeon
is responsible for the choice of the prosthesis used when dealing with their
patients<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>Bioprosthetic valves of higher durability and also of very high cost have been
developed, but they are not available to the general population, on the other hand,
less thrombogenic mechanical prostheses emerged. In the field of pharmacology, new
anticoagulants have been used in AF, but with high cost and no good results in
patients with mechanical valves, in such a way that in practice vitamin K
antagonists should still be used in patients with mechanical prostheses and patients
with AF and low purchasing power<sup>[<xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>The most commonly used vitamin K antagonists are warfarin and phenprocoumon, with
proven efficacy, although the treatment results need to maintain adequate levels of
anticoagulation. In order to control anticoagulation, we use the prothrombin time
(PT) test, which is sensitive to reductions of coagulation factors II, VII and X. In
1982, the World Health Organization adopted the international normalized ratio (INR)
calibration model, which reports the results of PT in a standardized way<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>The main complications caused by the use of these drugs are bleeding events, blood
dyscrasia, or thromboembolic events resulting from inadequate levels of
anticoagulation<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>, which
occur due to several factors, among them are: patient's difficult access to
treatment (related to socioeconomic and cultural factors), and the difficulty of
maintaining the INR in the therapeutic values for food and drug
interactions<sup>[<xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>Most anticoagulation studies are prospective and it is known that when entering
patient in a research protocol the outcomes are different from that observed in
clinical practice because the follow-up of these patients is more stringent.
Considering that even in prospective studies the rate of complications is not
negligible and little more than half of patients achieve therapeutic INR, it is
necessary to reflect that in clinical practice the results can be even worse. Thus,
the design of this study was performed in order to eliminate the intervention of the
researcher on the results and evaluate in a retrospective cohort study what happened
to the patient in the last year of anticoagulation until the date of his inclusion
in the study.</p><p>The aim of this study was to assess the incidence of embolic and hemorrhagic
complications in anticoagulated patients with vitamin K antagonists and the
relationship with socioeconomic and cultural factors, in addition to assessing the
quality of treatment by the number of consultations and the INR number in
therapeutic goal.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a retrospective cohort study which analyzed 100 consecutive patients using
oral anticoagulation with vitamin K antagonists (warfarin and phenprocoumon), who
came for consultation in outpatient cardiac surgery and private practice of the
cardiac surgery team of Santa Casa de Miseric&#x000f3;rdia de Ponta Grossa, PR,
Brazil, from January 2011 to December 2014.</p><p>The study included patients with mechanical prostheses and AF, all under use of
warfarin or phenprocoumon who agreed to participate. Patients who underwent surgery
in the service, but who made use of anticoagulation control with their respective
clinicians, did not participate in the study.</p><p>Socioeconomic status, clinical and anticoagulation data in the last year prior to the
time of inclusion in the study were collected using interviews with the patient and
hospital records consultation. The following negative outcomes considered were: a)
embolic or hemorrhagic complications; b) inadequate treatment. It was considered as
embolic complication any symptomatic ischemic event; bleeding events were considered
as the situations that led to the discontinuation of anticoagulation and may be
smaller events (without admission) and major events (requiring hospitalization).
Major complications were considered as bleeding requiring hospitalization and
thromboembolic events.</p><p>It was considered as inappropriate treatment the performance of less than 8 annual
PTs (all patients were instructed to perform at least one monthly exam) or when the
INR was outside the therapeutic target in more than 40% of the tests. The
therapeutic target considered was INR between 2.5 and 3.5 for mitral valve
prosthesis<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> and between
2 and 3 for reasons other anticoagulation<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p><p>Regarding the statistical analysis, for continuous variables we used the mean
&#x000b1; standard deviation, compared by the Student's t test, and categorical
variables were compared by chi-square test with Yates correction and logistic
regression. <italic>P</italic>-value less than 0.05 were considered significant.</p><p>All patients signed a written free and informed consent, according to Resolution
196/96. The study was approved by the Research Ethics Committee of the Universidade
Estadual de Ponta Grossa, Paran&#x000e1;, Brazil, according to protocol 06532/11.</p></sec><sec sec-type="results"><title>RESULTS</title><p>The basic characteristics of the sample are presented in <xref ref-type="table" rid="t1">Table 1</xref>; in which we can observe that there was a similar
distribution between the genders, with 73% of patients aged less than or equal to 65
years. As to the place of origin: 66% of the sample resides in municipalities with
less than 60,000 inhabitants around Ponta Grossa (regional center city with 311,611
inhabitants, according to the last census) and up to 30% live in rural areas.
Regarding education, the group showed a 10% illiteracy rate and 66% only studied up
to the 4<sup>th</sup> grade of elementary school, showing a low education level of
the sample. The average number of consultations per year was 3.2&#x000b1;1.6, 52% of
patients were SUS users. As anticoagulation indication, 71 were patients with
mechanical valve prostheses and 29 had AF; the anticoagulation presented with an
average time of 5&#x000b1;3.7 years.</p><p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Basic characteristics of the patients assessed.</p></caption><table frame="box" rules="all" style="border-right:hidden;border-left:hidden"><colgroup span="1"><col width="90%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><bold>Characteristics</bold></th><th align="center" rowspan="1" colspan="1"><bold>Patients n=100</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>SOCIOCULTURAL ASPECTS</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Gender</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">46</td></tr><tr><td rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 65 years</td><td align="center" rowspan="1" colspan="1">73</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 65 years</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td rowspan="1" colspan="1"><bold>Location</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ponta Grossa (311,611
inhabitants according to IBGE)</td><td align="center" rowspan="1" colspan="1">34</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other (cities in the region with
less than 60,000 inhabitants)</td><td align="center" rowspan="1" colspan="1">66</td></tr><tr><td rowspan="1" colspan="1"><bold>Area</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Urban</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Rural</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1"><bold>Schooling</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Illiterate</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1<sup>st</sup> to 4<sup>th</sup>
grade</td><td align="center" rowspan="1" colspan="1">61</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4<sup>th</sup> to 8<sup>th</sup>
grade</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1<sup>st</sup> to 3<sup>rd</sup>
year of high school</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Higher Education</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"><bold>Health insurance</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;SUS</td><td align="center" rowspan="1" colspan="1">52</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Private</td><td align="center" rowspan="1" colspan="1">48</td></tr><tr><td rowspan="1" colspan="1"><bold>Medical consultations/year</bold></td><td align="center" rowspan="1" colspan="1">3.2&#x000b1;1.6</td></tr><tr><td colspan="2" rowspan="1"><bold>CLINICAL ASPECTS</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Indication of anticoagulation</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mechanical prosthesis</td><td align="center" rowspan="1" colspan="1">71</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td rowspan="1" colspan="1"><bold>Type of medicine</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Warfarin</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Phenprocoumon</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1"><bold>Time of anticoagulation in years</bold></td><td align="center" rowspan="1" colspan="1">5.0&#x000b1;3.7</td></tr><tr><td rowspan="1" colspan="1"><bold>Number of change dosage/year</bold></td><td align="center" rowspan="1" colspan="1">1.6&#x000b1;1.8</td></tr><tr><td colspan="2" rowspan="1"><bold>NEGATIVE OUTCOMES: inadequate
treatment</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Annual PTs insufficient number (&#x0003c; 8)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">36</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td rowspan="1" colspan="1"><bold>Percentage of INR outside the target (inappropriate
treatment)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;More than 40%</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;40% or less</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1"><bold>NEGATIVE OUTCOMES: complications</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Hemorrhagic complications</bold></td><td align="center" rowspan="1" colspan="1">29</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Nasal</td><td align="center" rowspan="1" colspan="1">9 (31%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Oral</td><td align="center" rowspan="1" colspan="1">2 (7%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Genitourinary</td><td align="center" rowspan="1" colspan="1">4 (14%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Gastrointestinal</td><td align="center" rowspan="1" colspan="1">5 (17%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Bruises</td><td align="center" rowspan="1" colspan="1">2 (7%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Skin</td><td align="center" rowspan="1" colspan="1">7 (24%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Need for Hospitalization</td><td align="center" rowspan="1" colspan="1">7 (24%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Embolic complications</bold></td><td align="center" rowspan="1" colspan="1">2</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ischemic cerebrovascular
accident</td><td align="center" rowspan="1" colspan="1">1 (50%)</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Retinal embolism</td><td align="center" rowspan="1" colspan="1">1 (50%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Total of major complications</bold></td><td align="center" rowspan="1" colspan="1">9 (9%)</td></tr></tbody></table><table-wrap-foot><p>IBGE=Brazilian Institute of Geography and Statistics;</p><p>INR=lnternational standard ratio; PT=prothrombin time;</p><p>SUS=Unified Health System (Brazilian public health system)</p></table-wrap-foot></table-wrap>
</p><p>During the study period, 70 patients were outside of therapeutic level (more than 40%
of PTs), and 76 performed at least 8 annual PTs. Only 21 patients were considered as
proper treatment (therapeutic INR in at least 60% of PTSs and performing at least 8
annual examinations). Nearly a third of patients (n=29) had some kind of bleeding,
and of these, seven required hospitalization for treatment of bleeding. There were 2
embolic episodes, one for central nervous system and 1 retinal (<xref ref-type="table" rid="t1">Table 1</xref>); totaling 9 major complications,
namely, those that needed to be hospitalized or had embolism episodes.</p><p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Distribution of patients for the presence of inappropriate treatment.</p></caption><table frame="box" rules="all" style="border-right:hidden;border-left:hidden"><colgroup span="1"><col width="20%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="6%" span="1"/><col width="18%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="6%" span="1"/><col width="18%" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">&#x000a0;</th><th colspan="4" align="center" rowspan="1"><bold>INR outside the target in more
than 40%</bold></th><th colspan="4" align="center" rowspan="1"><bold>Number of insufficient PTs &#x0003c;
8</bold></th></tr><tr><th align="center" rowspan="1" colspan="1"><bold>No n=30</bold></th><th align="center" rowspan="1" colspan="1"><bold>Yes n=70</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic><xref ref-type="table-fn" rid="TFN3">*</xref></bold></th><th align="center" rowspan="1" colspan="1"><bold>OR (C) <italic>P</italic><xref ref-type="table-fn" rid="TFN4">**</xref></bold></th><th align="center" rowspan="1" colspan="1"><bold>No n=64</bold></th><th align="center" rowspan="1" colspan="1"><bold>Yes n=36</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic><xref ref-type="table-fn" rid="TFN3">*</xref></bold></th><th align="center" rowspan="1" colspan="1"><bold>OR (C) <italic>P</italic><xref ref-type="table-fn" rid="TFN4">**</xref></bold></th></tr></thead><tbody><tr><td colspan="9" rowspan="1"><bold>SOCIOCULTURAL ASPECTS</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Gender</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">21 (70%)</td><td align="center" rowspan="1" colspan="1">33 (47%)</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">2.61 (6.5-1.0) 0.04</td><td align="center" rowspan="1" colspan="1">35 (55%)</td><td align="center" rowspan="1" colspan="1">19 (53%)</td><td align="center" rowspan="1" colspan="1">0.85</td><td align="center" rowspan="1" colspan="1">1.08 (0.47-2.45) 0.85</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">9 (30%)</td><td align="center" rowspan="1" colspan="1">37 (53%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">29 (45%)</td><td align="center" rowspan="1" colspan="1">17 (47%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 65 years</td><td align="center" rowspan="1" colspan="1">22 (73%)</td><td align="center" rowspan="1" colspan="1">51 (73%)</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">1.02 (0.39-2.69) 0.96</td><td align="center" rowspan="1" colspan="1">50 (78%)</td><td align="center" rowspan="1" colspan="1">23 (64%)</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">2.01 ( -5.0 0.82) 0.13</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 65 years</td><td align="center" rowspan="1" colspan="1">8 (27%)</td><td align="center" rowspan="1" colspan="1">19 (27%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">14 (22%)</td><td align="center" rowspan="1" colspan="1">13 (36%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Location</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ponta Grossa</td><td align="center" rowspan="1" colspan="1">10 (33%)</td><td align="center" rowspan="1" colspan="1">24 (34%)</td><td rowspan="2" align="center" colspan="1">0.93</td><td rowspan="2" align="center" colspan="1">0.84 ( -2.07 0.34) 0.71</td><td align="center" rowspan="1" colspan="1">20 (31%)</td><td align="center" rowspan="1" colspan="1">14 (39%)</td><td rowspan="2" align="center" colspan="1">0.58</td><td rowspan="2" align="center" colspan="1">1.4 (0.59 -3.3) 0.44</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">20 (67%)</td><td align="center" rowspan="1" colspan="1">46 (66%)</td><td align="center" rowspan="1" colspan="1">44 (69%)</td><td align="center" rowspan="1" colspan="1">22 (61%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Area</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Urban</td><td align="center" rowspan="1" colspan="1">18 (60%)</td><td align="center" rowspan="1" colspan="1">52 (74%)</td><td rowspan="2" align="center" colspan="1">0.24</td><td rowspan="2" align="center" colspan="1">0.48 (0.17 -1.33) 0.14</td><td align="center" rowspan="1" colspan="1">43 (67%)</td><td align="center" rowspan="1" colspan="1">27 (75%)</td><td rowspan="2" align="center" colspan="1">0.55</td><td rowspan="2" align="center" colspan="1">1.46 (0.58 -3.67) 0.41</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Rural</td><td align="center" rowspan="1" colspan="1">12 (40%)</td><td align="center" rowspan="1" colspan="1">18 (26%)</td><td align="center" rowspan="1" colspan="1">21 (33%)</td><td align="center" rowspan="1" colspan="1">9 (25%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Schooling</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 4 years</td><td align="center" rowspan="1" colspan="1">22 (73%)</td><td align="center" rowspan="1" colspan="1">49 (70%)</td><td rowspan="2" align="center" colspan="1">0.92</td><td rowspan="2" align="center" colspan="1">1.18 (0.45 -3.07) 0.73</td><td align="center" rowspan="1" colspan="1">47 (73%)</td><td align="center" rowspan="1" colspan="1">24 (67%)</td><td rowspan="2" align="center" colspan="1">0.63</td><td rowspan="2" align="center" colspan="1">1.38 (0.57-3.36) 0.47</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 4 years</td><td align="center" rowspan="1" colspan="1">8 (27%)</td><td align="center" rowspan="1" colspan="1">21 (30%)</td><td align="center" rowspan="1" colspan="1">17 (27%)</td><td align="center" rowspan="1" colspan="1">12 (33%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Health insurance</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;SUS</td><td align="center" rowspan="1" colspan="1">15 (50%)</td><td align="center" rowspan="1" colspan="1">37 (53%)</td><td rowspan="2" align="center" colspan="1">0.96</td><td rowspan="2" align="center" colspan="1">0.89 ( -2.1 0.38) 0.79</td><td align="center" rowspan="1" colspan="1">32 (50%)</td><td align="center" rowspan="1" colspan="1">20 (55%)</td><td rowspan="2" align="center" colspan="1">0.74</td><td rowspan="2" align="center" colspan="1">0.95 (0.42-2.16) 0.91</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">15 (50%)</td><td align="center" rowspan="1" colspan="1">33 (47%)</td><td align="center" rowspan="1" colspan="1">32 (50%)</td><td align="center" rowspan="1" colspan="1">16 (45%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Medical consultations/year</bold></td><td align="center" rowspan="1" colspan="1">3.1&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">3.2 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">3.5 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">2.7 (&#x000b1;1.3)</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="9" rowspan="1"><bold>CLINICAL ASPECTS</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Indication of anticoagulation</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">8 (27%)</td><td align="center" rowspan="1" colspan="1">21 (30%)</td><td rowspan="2" align="center" colspan="1">0.92</td><td rowspan="2" align="center" colspan="1">1.18 (0.45-3.07) 0.73</td><td align="center" rowspan="1" colspan="1">16 (25%)</td><td align="center" rowspan="1" colspan="1">13 (36%)</td><td rowspan="2" align="center" colspan="1">0.34</td><td rowspan="2" align="center" colspan="1">1.7 (0.7 -4.1) 0.24</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mechanical prosthesis</td><td align="center" rowspan="1" colspan="1">22 (73%)</td><td align="center" rowspan="1" colspan="1">49 (70%)</td><td align="center" rowspan="1" colspan="1">48 (75%)</td><td align="center" rowspan="1" colspan="1">23 (64%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Type medicine</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Warfarin</td><td align="center" rowspan="1" colspan="1">20 (67%)</td><td align="center" rowspan="1" colspan="1">50 (71%)</td><td rowspan="2" align="center" colspan="1">0.81</td><td rowspan="2" align="center" colspan="1">0.60 (0.24-1.47) 0.27</td><td align="center" rowspan="1" colspan="1">45 (70%)</td><td align="center" rowspan="1" colspan="1">25 (69%)</td><td rowspan="2" align="center" colspan="1">0.93</td><td rowspan="2" align="center" colspan="1">0.9 (-2.17 0.37) 0.82</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Phenprocoumon</td><td align="center" rowspan="1" colspan="1">10 (33%)</td><td align="center" rowspan="1" colspan="1">20 (29%)</td><td align="center" rowspan="1" colspan="1">19 (30%)</td><td align="center" rowspan="1" colspan="1">11 (31%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Time of anticoagulation</bold></td><td align="center" rowspan="1" colspan="1">5.3&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">4.9&#x000b1;4.0</td><td align="center" rowspan="1" colspan="1">0.40</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">4.4&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">6.1&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"><bold>Change of dosage</bold></td><td align="center" rowspan="1" colspan="1">1.1&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;2.0</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">2.0&#x000b1;2.0</td><td align="center" rowspan="1" colspan="1">0.9&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="9" rowspan="1"><bold>NEGATIVE OUTCOMES: complications</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>All the complications</bold></td><td align="center" rowspan="1" colspan="1">7 (23%)</td><td align="center" rowspan="1" colspan="1">23 (33%)</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">1.61 (0.60-4.30) 0.34</td><td align="center" rowspan="1" colspan="1">17 (27%)</td><td align="center" rowspan="1" colspan="1">13 (36%)</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">1.56 (0.65 -3.76) 0.32</td></tr><tr><td rowspan="1" colspan="1"><bold>Major complications</bold></td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">8 (11%)</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">3.74 (0.45-31.33) 0.16</td><td align="center" rowspan="1" colspan="1">3 (5%)</td><td align="center" rowspan="1" colspan="1">6 (17%)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">4.06 (1.00-17.30) 0.05</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>INR= International Normalized Ratio; SUS=Unified Health System;
NA=not applicable</p></fn><fn id="TFN3"><label>*</label><p>Student t test and Chi-square test with Yates correction;</p></fn><fn id="TFN4"><label>**</label><p>Logistic Regression</p></fn></table-wrap-foot></table-wrap>
</p><p><xref ref-type="table" rid="t2">Table 2</xref> shows the analysis of the factors
influencing the suitability for treatment. When comparing the genders, women have
more INR outside the target (OR=2.61; C.I.=1.0 to 6.5; <italic>P</italic>=0.04).
Sociocultural factors such as age, origin city, urban or rural dweller, education,
SUS or private system users, as well as the type of anticoagulant (warfarin or
phenprocoumon) and anticoagulation reason (mechanical valve or AF) did not
significantly interfere with the occurrence of treatment considered inappropriate
(insufficient number of PTs performed and low percentage of therapeutic INR). The
average annual consultations was significantly lower among patients who had
insufficient number of PTs (<italic>P</italic>=0.02). Regarding anticoagulation
time, those with number of PTs smaller than 8 year averaged 6.1 years of
anticoagulation <italic>versus</italic> 4.4 years than those who performed
satisfactory number of PTs, showing a tendency to worsening of patient care with
their INR control over time (<italic>P</italic>=0.03). As expected, those who had
number of PTs lower than 8 in one year had less adjustments in dosage
(<italic>P</italic>=0.003). The major complications in patients with
insufficient number of PTs were 5, since those with sufficient number of tests
amounted to 3; generating a tendency to a significant difference between these
groups, with an OR of 4.06 (C.I.=0.95-17.40, <italic>P</italic>=0.05). The quality
of care was not related to the occurrence of major and minor complications.</p><p><xref ref-type="table" rid="t3">Table 3</xref> analyzes the epidemiological
characteristics of patients in relation to major complications, and showed that
patients with a higher anticoagulation time were more likely to have complications
(<italic>P</italic>=0.001). The other factors were not associated with the
presence of major complications.</p><p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Analysis of the epidemiological and clinical characteristics of patients
in relation to major complications.</p></caption><table frame="box" rules="all" style="border-right:hidden;border-left:hidden"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th colspan="5" align="left" rowspan="1"><bold>Major complications</bold></th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>Yes n=9</bold></th><th align="center" rowspan="1" colspan="1"><bold>No n=91</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic><xref ref-type="table-fn" rid="TFN6">*</xref></bold></th><th align="center" rowspan="1" colspan="1"><bold>OR (C) <italic>P</italic><xref ref-type="table-fn" rid="TFN7">**</xref></bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 65 years</td><td align="center" rowspan="1" colspan="1">6 (67%)</td><td align="center" rowspan="1" colspan="1">67 (74%)</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">1.39 (0.32-6.02) 0.66</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265; 65 years</td><td align="center" rowspan="1" colspan="1">3 (33%)</td><td align="center" rowspan="1" colspan="1">24 (26%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Gender</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">5 (56%)</td><td align="center" rowspan="1" colspan="1">49 (54%)</td><td align="center" rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">0.93 (0.23-3.70) 0.92</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">4 (44%)</td><td align="center" rowspan="1" colspan="1">42 (46%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Schooling</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 4 years</td><td align="center" rowspan="1" colspan="1">7 (78%)</td><td align="center" rowspan="1" colspan="1">64 (70%)</td><td align="center" rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">0.68 (0.13-3.47) 0.63</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 4 years</td><td align="center" rowspan="1" colspan="1">2 (22%)</td><td align="center" rowspan="1" colspan="1">27 (30%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Area</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Urban</td><td align="center" rowspan="1" colspan="1">6 (67%)</td><td align="center" rowspan="1" colspan="1">64 (70%)</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.84 ( -3.62 0.20) 0.82</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Rural</td><td align="center" rowspan="1" colspan="1">3 (33%)</td><td align="center" rowspan="1" colspan="1">27 (30%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Location</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ponta Grossa</td><td align="center" rowspan="1" colspan="1">4 (44%)</td><td align="center" rowspan="1" colspan="1">30 (33%)</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">1.63 (0.41-6.50) 0.49</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">5 (56%)</td><td align="center" rowspan="1" colspan="1">61 (67%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Medical consultations/year</bold></td><td align="center" rowspan="1" colspan="1">2.4+1.2</td><td align="center" rowspan="1" colspan="1">3.3&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"><bold>Health insurance</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;SUS</td><td align="center" rowspan="1" colspan="1">5 (56%)</td><td align="center" rowspan="1" colspan="1">47 (52%)</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">( -3.39 0.22) 0.83 0.85</td></tr><tr style="border-top:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">4 (44%)</td><td align="center" rowspan="1" colspan="1">44 (48%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><bold>Time of anticoagulation</bold></td><td align="center" rowspan="1" colspan="1">8.8&#x000b1;6.1</td><td align="center" rowspan="1" colspan="1">4.6&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"><bold>Change of Dosage</bold></td><td align="center" rowspan="1" colspan="1">1.1&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">1.6&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">0.43</td><td align="center" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>SUS=Unified Health System; NA=not applicable</p></fn><fn id="TFN6"><label>*</label><p>Student t test and Chi-square test with Yates correction;</p></fn><fn id="TFN7"><label>**</label><p>Regression</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In general, the studies on the anticoagulation are controlled, not depicting the
reality experienced daily in doctors' offices and SUS clinics. This study was
performed in order to identify some of the factors related to the quality of
anticoagulation and possible complications, embolic or bleeding, in patients on oral
anticoagulation therapy with vitamin K antagonists, experienced in clinical
practice. Thus, we opted for a retrospective cohort study, so that the data
collected were related to one year before the patients entered the study, so without
interference from the researchers control. The study included patients with regular
monitoring in the outpatient cardiac surgery, whose anticoagulation is under the
supervision of the surgical team. Patients who underwent surgery in the service but
who were followed-up by their respective clinicians were excluded from the study.
That is the reason for the relatively small number of patients included.</p><p>AF, a common arrhythmia, with an estimated prevalence of 0.4% in the general
population<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>, was
present in 29 patients studied. It is estimated that it is responsible for about 5%
of the annual incidence of cerebrovascular accident worldwide<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, and current evidence suggests
that anticoagulation reduces the incidence of about 70 to 80%<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Although new anticoagulants have shown effectiveness
equal to vitamin K antagonists and with the advantage of presenting less bleeding
and exempt the PT exams, the cost of these medications still does not allow the use
indiscriminately and have not been approved for use in patients with valvular heart
disease or prostheses; as the study was performed at a heart surgery clinic, the
possibility of use of new drugs is reduced, because of the predominant population of
patients with prostheses and valvular heart disease. New studies attempt to assess
the use of new anticoagulants in patients with valvular or mechanical prosthesis;
but none showed benefits, some show even worse results compared to vitamin K
antagonists<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>In patients with valvular prosthesis, anticoagulation therapy varies according to the
type and position of such device, being mandatory in patients with mechanical
prostheses<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Although warfarin and
phenprocoumon reduce thromboembolic complications in patients with AF or mechanical
heart valves, the effective management is complex and bleeding events are the main
complication of this class of drugs<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, data that are consistent with the findings of this cohort
study, in which the number of bleeding episodes was high (29%); if we consider only
the major events, the rate is still higher than the literature: 2 embolic events and
7 bleeding requiring hospitalization.</p><p>In a developing country like Brazil, access to health care is not always easy. Often,
patients do not perform all the necessary examinations, or they do not perform as
often as necessary so that they can get good therapeutic results. The average annual
consultations found in this study was 3.2&#x000b1;1.6, lower than four annual visits
recommended by the team. The Brazilian guidelines of valvular heart disease makes no
recommendations as to the time interval between postoperative visits, European
guidelines recommend intervals of six months; in this service patients usually are
re-evaluated every three months because it is a time considered safe by the group to
keep good surveillance in anticoagulated patients<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. A
national study of anticoagulation in specialized clinics shows an even higher
frequency of consultations<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.
Data from national and international literature indicate that about 40% to 50% of
anticoagulation therapy in patients are outside the target<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. These figures are even worse in
this sample, 70% of the examinations were outside the desired level.</p><p>One possible explanation for the high number of patients outside the therapeutic
level and for major bleeding index may be the fact that this study is a sample of
reality, in which the patients were not noticed they were part of a prospective
study, as in large clinical trials.</p><p>Better anticoagulation control has been related to the educational level of the
patients<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, but in this
series patients who studied four years or more did not have better quality of
treatment, either by the number of tests performed or the percentage of INR in the
therapeutic range.</p><p>Little is known about the extent to which socioeconomic conditions may influence the
risk of bleeding. Some data suggest that low social status is associated with an
increased risk of bleeding in the general population, as well as those receiving
anticoagulants. The lower socioeconomic status is associated with less access to
health<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Cressman et
al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> divided the Canadian
population into quintiles by income, classified according to the average income of
the neighborhood where the patient lived and found that patients in the quintile
with the lowest income had higher risk of bleeding than those in the highest income
quintile (adjusted risk ratio 1.18, 95% CI 1.12-1.23). In secondary analysis, they
identified a similar association between socioeconomic status and risk of fatal
bleeding with patients in the lowest income quintile having 28% more likely to die
of bleeding associated with warfarin than those in the quintile with the highest
income (adjusted risk ratio 1.28, 95% CI 1.11-1.48). In an analysis by bleeding
subtype, they found that individuals in the quintile with the lowest income had an
increased risk of gastrointestinal bleeding (adjusted hazard ratio 1.18, 95% CI
1.10-1.27) and other bleeding subtypes (adjusted hazard ratio 1.20, 95% CI
1.12-1.29) than those in the highest income quintile, with lower degrees of risk
among patients in quintiles 2, 3 and 4. Interestingly, however, they found no
association between socioeconomic status and risk of intracranial
hemorrhage<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. In this
sample the socioeconomic aspects, based on the monetary status were not studied. But
when considering patients from the private system and the public health system,
there were no differences between complications or quality of anticoagulation. There
was, in this sample, great variability in patients' age since older patients with
coronary artery disease and AF or degenerative valvular disease were included in the
study, as well as younger patients with mechanical valves due to rheumatic
fever.</p><p>Although the female and old age are considered risk factors for bleeding<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>, there was no significant difference in patients aged over
65 or between men and women, which was also found in another observational
study<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. But it was
observed that women had less percentage of therapeutic INR than men.</p><p>In this study, we can be observe that in the group that had insufficient number of TP
in a year had longer anticoagulant time and fewer consultations in a year, which
also resulted in a smaller number of changes in posology; highlighting the
difficulty of maintaining an anticoagulation treatment in our country, especially
with the passage of time when patients become less careful with their
anticoagulation. Avila et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>
showed that patients with lower anticoagulation time presented more stable INR than
those with long-term use of anticoagulants.</p><p>An important point of this study was that the group that had insufficient number of
PTs tended to a greater number of major complications (OR:4.06, CI: 1.01-17.40;
<italic>P</italic>:0.05); showing that inadequate control of therapy increases
the risk of hospitalization and bleeding and thromboembolic events in this group.
Regarding anticoagulation time, patients who had major complications were twice as
long than those who had no complications (<italic>P</italic>=0.001), noting that the
higher anticoagulation time the greater the negligence on the part of the patient to
treatment and consequently increased number of complications.</p><p>Adherence to treatment with oral anticoagulation is one of the most important factors
for the achievement of the optimal level of anticoagulation<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, but the factors that lead to
poor adherence have been poorly understood<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Some listed factors relate to the patient, disease,
treatment, health services and social support<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>In view of the various factors that affect the response to warfarin<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, including the intake of vitamin
K (more present in some foods, such as avocados, broccoli, spinach and
cauliflower<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>),
adherence to treatment<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>,
genetic factors, drug interactions<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, age<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>,
comorbidities, socioeconomic factors<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, among others, becomes necessary the publication of more
studies to investigate these factors in order to reduce the incidence of
complications related to anticoagulation, yet very common in our environment.</p><p>Treatment of anticoagulation in our country is based on data from other countries.
With this study we note the need to expand national studies, as the factors that
influence adherence to treatment have their local characteristics.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In our sample the rate of major complications and INR outside the therapeutic target
was high. Female patients had less INR in therapeutic goal. Fewer annual PTs were
related to longer duration of anticoagulation, less annual consultations and less
dose adjustments. More major complications occurred in patients with longer duration
of anticoagulation. It is, therefore, the longer period of anticoagulation the
factor more related to inadequate treatment and complications.</p><p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="15%" span="1"/><col width="85%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Authors' roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">MACC</td><td rowspan="1" colspan="1">Conception and design study; realization of operations and/or
trials; statistical analysis; analysis and/or data
interpretation; manuscript writing or critical review of its
content; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">LKK</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; statistical analysis;
manuscript writing or critical review of its content; final
manuscript approval</td></tr><tr><td rowspan="1" colspan="1">JSG</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript writing or
critical review of its content; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">MDS</td><td rowspan="1" colspan="1">Statistical analysis; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">RZG</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; final manuscript
approval</td></tr><tr><td rowspan="1" colspan="1">ESSR</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; final manuscript
approval</td></tr></tbody></table></table-wrap>
</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Universidade de Ponta Grossa (UEPG), PR, Brazil
and Santa Casa de Miseric&#x000f3;rdia de Ponta Grossa, Ponta Grossa, PR, Brazil.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>AH</given-names></name><name><surname>Wender</surname><given-names>OC</given-names></name><name><surname>Almeida</surname><given-names>AS</given-names></name><name><surname>Soares</surname><given-names>LE</given-names></name><name><surname>Picon</surname><given-names>PD</given-names></name></person-group><article-title>Comparison of clinical outcomes in patients undergoing mitral
valve replacement with mechanical or biological substitutes: a 20 years
cohort</article-title><source>BMC Cardiovasc Disord</source><year>2014</year><volume>14</volume><fpage>146</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">25326757</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>JM</given-names></name><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Booth</surname><given-names>ME</given-names></name><name><surname>Dokholyan</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Long-term safety and effectiveness of mechanical versus biologic
aortic valve prostheses in older patients: results from the Society of
Thoracic Surgeons Adult Cardiac Surgery National Database</article-title><source>Circulation</source><year>2013</year><volume>127</volume><issue>16</issue><fpage>1647</fpage><lpage>1655</lpage><pub-id pub-id-type="pmid">23538379</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>CV</given-names><suffix>Junior</suffix></name><name><surname>Fenelon</surname><given-names>G</given-names></name><name><surname>Soeiro</surname><given-names>AM</given-names></name><name><surname>Nicolau</surname><given-names>JC</given-names></name><name><surname>Piegas</surname><given-names>LS</given-names></name><name><surname>Montenegro</surname><given-names>ST</given-names></name><etal/><collab>Sociedade Brasileira de Cardiologia</collab></person-group><article-title>Diretrizes Brasileiras de Antiagregantes Plaquet&#x000e1;rios e
Anticoagulantes em Cardiologia</article-title><source>Arq Bras Cardiol</source><year>2013</year><volume>101</volume><issue>3</issue><supplement>Supl.3</supplement><fpage>1</fpage><lpage>93</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Savelieva</surname><given-names>I</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Hohnloser</surname><given-names>SH</given-names></name><etal/></person-group><article-title>2012 focused update of the ESC Guidelines for the management of
atrial fibrillation: an update of the 2010 ESC Guidelines for the management
of atrial fibrillation. Developed with the special contribution of the
European Heart Rhythm Association</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>21</issue><fpage>2719</fpage><lpage>2747</lpage><pub-id pub-id-type="pmid">22922413</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keogh</surname><given-names>C</given-names></name><name><surname>Wallace</surname><given-names>E</given-names></name><name><surname>Dillon</surname><given-names>C</given-names></name><name><surname>Dimitrov</surname><given-names>BD</given-names></name><name><surname>Fahey</surname><given-names>T</given-names></name></person-group><article-title>Validation of the CHADS2 clinical prediction rule to predict
ischaemic stroke. A systematic review and meta-analysis</article-title><source>Thromb Haemost</source><year>2011</year><volume>106</volume><issue>3</issue><fpage>528</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">21800003</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Nieuwlaat</surname><given-names>R</given-names></name><name><surname>Pisters</surname><given-names>R</given-names></name><name><surname>Lane</surname><given-names>DA</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name></person-group><article-title>Refining clinical risk stratification for predicting stroke and
thromboembolism in atrial fibrillation using a novel risk factor-based
approach: the euro heart survey on atrial fibrillation</article-title><source>Chest</source><year>2010</year><volume>137</volume><issue>2</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">19762550</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisters</surname><given-names>R</given-names></name><name><surname>Lane</surname><given-names>DA</given-names></name><name><surname>Nieuwlaat</surname><given-names>R</given-names></name><name><surname>de Vos</surname><given-names>CB</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>A novel user-friendly score (HAS-BLED) to assess 1-year risk of
major bleeding in patients with atrial fibrillationthe: Euro Heart
Survey</article-title><source>Chest</source><year>2010</year><volume>138</volume><issue>5</issue><fpage>1093</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">20299623</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eikelboom</surname><given-names>JW</given-names></name><name><surname>Connolly</surname><given-names>SJ</given-names></name><name><surname>Brueckmann</surname><given-names>M</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Dabigatran versus warfarin in patients with mechanical heart
valves</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>13</issue><fpage>1206</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">23991661</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cressman</surname><given-names>AM</given-names></name><name><surname>Macdonald</surname><given-names>EM</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Gomes</surname><given-names>T</given-names></name><name><surname>Paterson</surname><given-names>JM</given-names></name><etal/><collab>Canadian Drug Safety and Effectiveness Research Network</collab></person-group><article-title>Socioeconomic status and risk of hemorrhage during warfarin
therapy for atrial fibrillation: a population-based study</article-title><source>Am Heart J</source><year>2015</year><volume>170</volume><issue>1</issue><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">26093874</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zough</surname><given-names>F</given-names></name><name><surname>Tafreshi</surname><given-names>J</given-names></name><name><surname>Pai</surname><given-names>RG</given-names></name></person-group><article-title>Dabigatran use in mechanical heart valve patients</article-title><source>Future Cardiol</source><year>2014</year><volume>10</volume><issue>1</issue><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">24344656</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>NL</given-names></name><name><surname>Andrade</surname><given-names>RR</given-names></name><name><surname>Silva</surname><given-names>MA</given-names></name></person-group><article-title>Oral anticoagulation in carriers of mechanical heart valve
prostheses: experience of ten years</article-title><source>Rev Bras Cir Cardiovasc</source><year>2010</year><volume>25</volume><issue>4</issue><fpage>457</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">21340374</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lav&#x000ed;tola</surname><given-names>PL</given-names></name><name><surname>Spina</surname><given-names>GS</given-names></name><name><surname>Sampaio</surname><given-names>RO</given-names></name><name><surname>Tarasoutchi</surname><given-names>F</given-names></name><name><surname>Grinberg</surname><given-names>M</given-names></name></person-group><article-title>Bleeding during oral anticoagulant therapy: warning against a
greater hazard</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>2</issue><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">19838496</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matchar</surname><given-names>DB</given-names></name><name><surname>Jacobson</surname><given-names>A</given-names></name><name><surname>Dolor</surname><given-names>R</given-names></name><name><surname>Edson</surname><given-names>R</given-names></name><name><surname>Uyeda</surname><given-names>L</given-names></name><name><surname>Phibbs</surname><given-names>CS</given-names></name><etal/><collab>THINRS Executive Committee and Site Investigators</collab></person-group><article-title>Effect of home testing of international normalized ratio on
clinical events</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>17</issue><fpage>1608</fpage><lpage>1620</lpage><pub-id pub-id-type="pmid">20961244</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva Carvalho</surname><given-names>AR</given-names></name><name><surname>Dantas</surname><given-names>RA</given-names></name><name><surname>Pelegrino</surname><given-names>FM</given-names></name><name><surname>Corbi</surname><given-names>IS</given-names></name></person-group><article-title>Adaptation and validation of an oral anticoagulation measurement
of treatment adherence instrument</article-title><source>Rev Lat Am Enfermagem</source><year>2010</year><volume>18</volume><issue>3</issue><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">20721416</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avila</surname><given-names>CW</given-names></name><name><surname>Aliti</surname><given-names>GB</given-names></name><name><surname>Feij&#x000f3;</surname><given-names>MK</given-names></name><name><surname>Rabelo</surname><given-names>ER</given-names></name></person-group><article-title>Pharmacological adherence to oral anticoagulant and factors that
influence the international normalized ratio stability</article-title><source>Rev Lat Am Enfermagem</source><year>2011</year><volume>19</volume><issue>1</issue><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">21412625</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>J</given-names></name><name><surname>Zago</surname><given-names>AJ</given-names></name></person-group><article-title>Outpatient anticoagulation</article-title><source>Rev HCPA</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>30</fpage><lpage>38</lpage></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabral</surname><given-names>NL</given-names></name><name><surname>Volpato</surname><given-names>D</given-names></name><name><surname>Ogata</surname><given-names>TR</given-names></name><name><surname>Ramirez</surname><given-names>T</given-names></name><name><surname>Moro</surname><given-names>C</given-names></name><name><surname>Gouveia</surname><given-names>S</given-names></name></person-group><article-title>Fibrila&#x000e7;&#x000e3;o atrial cr&#x000f4;nica, AVC e
anticoagula&#x000e7;&#x000e3;o: sub-uso de warfarina?</article-title><source>Arq Neuro-Psiquiatr</source><year>2004</year><volume>62</volume><issue>4</issue><fpage>1016</fpage><lpage>1021</lpage></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louren&#x000e7;o</surname><given-names>DM</given-names></name><name><surname>Lopes</surname><given-names>LH</given-names></name><name><surname>Vignal</surname><given-names>CV</given-names></name><name><surname>Morelli</surname><given-names>VM</given-names></name></person-group><article-title>Clinical and laboratory evaluation of patients treated with oral
anticoagulation</article-title><source>Arq Bras Cardiol</source><year>1997</year><volume>68</volume><issue>5</issue><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">9497524</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasoutchi</surname><given-names>F</given-names></name><name><surname>Montera</surname><given-names>MW</given-names></name><name><surname>Grinberg</surname><given-names>M</given-names></name><name><surname>Barbosa</surname><given-names>MR</given-names></name><name><surname>Pi&#x000f1;eiro</surname><given-names>DJ</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>CRM</given-names></name><etal/></person-group><article-title>Diretriz Brasileira de Valvopatias - SBC 2011 / I Diretriz
Interamericana de Valvopatias - SIAC 2011</article-title><source>Arq Bras Cardiol</source><year>2011</year><volume>97</volume><issue>5</issue><supplement>supl. 1</supplement><fpage>1</fpage><lpage>67</lpage></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannegieter</surname><given-names>SC</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Wintzen</surname><given-names>AR</given-names></name><name><surname>van der Meer</surname><given-names>FJ</given-names></name><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name><name><surname>Bri&#x000eb;t</surname><given-names>E</given-names></name></person-group><article-title>Optimal oral anticoagulant therapy in patients with mechanical
heart valves</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><issue>1</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">7776988</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>HT</given-names></name><name><surname>Rabelo</surname><given-names>ER</given-names></name><name><surname>Aliti</surname><given-names>G</given-names></name><name><surname>Souza</surname><given-names>EN</given-names></name></person-group><article-title>Knowledge of patients with mechanical valve prostheses concerning
chronic oral anticoagulation therapy</article-title><source>Rev Lat Am Enfermagem</source><year>2010</year><volume>18</volume><issue>4</issue><fpage>696</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">20922315</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hylek</surname><given-names>EM</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Jensvold</surname><given-names>NG</given-names></name><name><surname>Henault</surname><given-names>LE</given-names></name><name><surname>Selby</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Effect of intensity of oral anticoagulation on stroke severity
and mortality in atrial fibrillation</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><issue>11</issue><fpage>1019</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">12968085</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>SJ</given-names></name><name><surname>Ezekowitz</surname><given-names>MD</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Eikelboom</surname><given-names>J</given-names></name><name><surname>Oldgren</surname><given-names>J</given-names></name><name><surname>Parekh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dabigatran versus warfarin in patients with atrial
fibrillation</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>12</issue><fpage>1139</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">19717844</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>AJ</given-names></name><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Bassetto</surname><given-names>S</given-names></name><name><surname>Alves</surname><given-names>L</given-names><suffix>Jr</suffix></name><name><surname>Scorzoni</surname><given-names>A</given-names><suffix>Filho</suffix></name><name><surname>Vicente</surname><given-names>WV</given-names></name></person-group><article-title>Isolated mitral and aortic valve replacement with the St. Jude
Medical valve: a midterm follow-up</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>3</issue><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">19851658</pub-id></element-citation></ref></ref-list></back></article>